Allogene expands CD19 rights to EU/UK; Q1 net loss $65M; cash $397M into 2026

Allogene Therapeutics, Inc.

2024-Q1 EPS reported -$0.38 revenue$22,000

Expanded CD19 oncology rights to all EU Member States and UK from Servier; combined market opportunity increased to >$9.5B from $6B.
Q1 2024 net loss of $65.0M ($0.38 per share); R&D expenses $52.3M, G&A $17.3M.
Cash, cash equivalents, and investments $397.3M as of March 31, 2024; cash runway expected into 2026.
Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL to start mid-2024; primary EFS data readout expected 2H 2026.
Initial data from Phase 1 cema-cel CLL trial expected by YE 2024; ALLO-329 IND planned Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-24-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.